Evidenced-Based Approach to Oropharynx Cancer, 2022 (2022 AMW)
2022 AAO-HNSF Annual Meeting & OTO Experience
HPV-associated oropharynx squamous cell carcinoma (OPSCC) is now one of the most common cancers faced by the Otolaryngology community. Treatment strategies for these patients continue to evolve rapidly because of new technologies including proton therapy, novel systemic therapies including immunotherapy and transoral robotic surgery (TORS). Current treatment approaches vary widely among institutions and national consensus guidelines remain vague. This expert lecture series will review the current best evidence to guide management decisions relevant to general otolaryngologists and head and neck specialists alike with a focus on the role of TORS in a multidisciplinary setting.
Credits
CME:1.0, MOC:1.0